The American College of Cardiology published its guide on a “practical approach” to mechanical circulatory support, with a focus on patients with cardiogenic shock or other high risk features and covers devices like Impella and TandemHeart as well as extracorporeal membrane oxygenation.
The Society for Cardiovascular Angiography and Interventions also released an update to its “best practices” guidelines for the cath lab, which includes new recommendations for radial access and the proper use of drugs brought to market since the last update in 2012.
To avoid confusion with the antiplatelet drug ticagrelor (Brilinta), the antidepressant vortioxetine has had its brand name changed from Brintellix to Trintellix. The FDA had previously warned about confusing the two brands, but continued reports of mix-ups prompted the change, which will start taking effect in June.
The Visia AF implantable cardioverter defibrillators (ICD), the first single-chamber, MRI-safe devices of their kind, have been approved by the FDA. Each ICD boasts of a (maximum) 11-year battery.
The FDA also approved gadobutrol (Gadavist), the first contrast agent for use with magnetic resonance angiography in patients with supra-aortic or renal artery disease.
ACCOAST investigators found that while patients with non-ST-segment elevation myocardial infarction getting prasugrel (Effient) treatment during percutaneous coronary intervention (PCI) did not have more major bleeding with transfemoral access, the transradial option yielded less major and minor bleeding combined.
Transcatheter aortic valve replacement (TAVR) in Asian countries was associated with no worse outcomes than previously seen in the West, “despite anatomical features of concern.”